September 29, 2022 7:51am

If you didn’t, be very cautious or just hold-on in any market or sector scenario; any market rebound will likely depend on whether Treasury yields continue to pull back

Indications: 5 Negative and 1 Positive Indications with 1 Pump/Promote (BSTG – the usual suspect)

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes

Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.56% or (-167 points), S&P futures are DOWN -0.76% or (-28 points) and NASDAQ futures are DOWN -1.07% or (-123 points) early in the pre-open – so far,

U.S. stock futures dived Thursday,

European markets are lower,

Asia-Pacific markets mostly rise.

 

Henry’omics:

Stock futures slumped Thursday, putting the major averages on track to give back some of the sharp gains seen in the previous session. <CNBC>

Indexes opened mixed but soon picked up momentum jumping with a comeback rally gaining steam Wednesday as U.S. Treasury yields retreated from multiyear highs.

The Dow closed UP +548.75 points (+1.88), the S&P closed UP +71.75 points (+1.97%) while the Nasdaq closed UP +22.13 points (+2.05%)

The Nasdaq is leading the monthly losses, down about 6.5%, while the Dow is -5.8% and S&P is -5.9% lower.

Economic Data Docket: The Commerce Department will release its final estimate of Q2 gross domestic product (revision) numbers and the Labor Department will release its count of new claims for workers filing for unemployment filings

 

RegMed Investors’ (RMi) closing bell: “time to make a portfolio buck and seek safety of cash. Probably early but, protective as Q3 comes to an end this week and earnings season LPS (loss-per-share) begins when the drama of low volume and upside pricing actions are suspect.” … https://www.regmedinvestors.com/articles/12625

 

Ebb and flow:

Q3/22 – September – 1 holiday, 9 positive and 10 negative closes

•             August – 1 neutral, 11 positive and 11 negative closes

•             July - 1 holiday, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indication:

Maintaining SELL …

Beam Therapeutics (BEAM) closed up +$2.61 to $51.02 after Tuesday’s +$1.85 with a negative -$1.54 or -3.02% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$3.31 to $66.94 after Tuesday’s +$2.53, Monday’s -$2.06 after Friday’s -$1.74 and last Thursday’s -$1.75, with a negative -$0.44 or -0.66% pre-open indication,

Sage Therapeutics (SAGE) closed up +$1.67 to $40.23 after Tuesday’s +$0.89, Monday’s -$0.83 and Friday’s -$0.72 with a negative -$0.13 or -0.32% pre-open indication,

Vericel (VCEL) closed up +$1.26 to $24.90 with a negative -$0.10 or -0.40% pre-open indication,

Ultragenyx (RARE) closed up +$0.98 to $41.27 with a negative -$1.24 or -3% pre-open indication,

 

Positive Indications:

uniQure NV (QURE) closed up +$0.82 to $18.86 with a positive +$0.37 or +1.96% pre-open indication,

 

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$1.00 with 1,545 shares traded after Tuesday’s flat ($0.00) with 2,675 shares traded, Monday’s +$0.39 with 970 shares traded, Friday’s -$1.39 with 2,051 shares traded, Thursday’s FLAT again with 1,844 shares traded, and the previous Wednesday’s FLAT with 3,196 shares traded and Tuesday’s +$0.10 with 9,718 shares traded, <3-month average = 2,095>,

Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?

  • Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
  • What is DST Capital?  Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?  Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
  • Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?

 

The BOTTOM LINE: Reiterating, I believe the dramatic “ascension” of the sector on Wednesday and Tuesday on low volume is a cause of concern to this sector.

But I made MONEY and ADDED value to a portfolio of sector equities

Another storm coming … quarter (Q3) about to close … and then back to earnings season!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

As I continually write, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.